Comprehensive analysis of the leukocyte immunoglobulin-like receptor family in clear cell renal cell carcinoma.

Background: Renal cell carcinoma (RCC) is a malignant tumor originating from the renal tubular epithelium and is the 14th most common cancer worldwide, causing around 180,000 deaths annually. Clear cell renal cell carcinoma (ccRCC) is the predominant subtype, accounting for 70-80% of cases. The potential of the leukocyte immunoglobulin-like receptor (LILR) family members in tumor progression and immune evasion has garnered significant attention.

DERL3 facilitates the progression of clear cell renal cell carcinoma by promoting epithelial-mesenchymal transition via regulation of the TGFB1 pathway.

Background: Clear cell renal cell carcinoma (ccRCC) is a highly prevalent malignancy within the urinary system. The intrinsic heterogeneity and resistance to conventional chemotherapy and radiotherapy contribute to the poor prognosis of advanced ccRCC patients. DERL3, part of the Derlin protein family, was first identified for its critical role in endoplasmic reticulum stress.

Elevated histone deacetylase 10 expression promotes the progression of clear cell renal cell carcinoma by Notch-1-PTEN signaling axis.

Background: Clear cell renal cell carcinoma (ccRCC), the most common pathological subtype of kidney cancer, accounts for approximately 70% to 80% of all cases. Histone deacetylase 10 (HDAC10) belongs to the HDAC class IIb subgroup, one of the histone deacetylases (HDAC) family. Previous studies suggest that HDAC10 may regulate the development of multiple tumor types.